[{"Assets_0_Q3_USD":321233000.0,"CommonStockSharesOutstanding_0_Q3_shares":43369323.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-52719000.0,"NetIncomeLoss_1_Q3_USD":-22702000.0,"NetIncomeLoss_3_Q3_USD":-66277000.0,"StockholdersEquity_0_Q3_USD":263270000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":7408000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":22554000.0,"Ticker":"NTLA","CIK":"1652130","name":"INTELLIA THERAPEUTICS, INC.","OfficialName":"Intellia Therapeutics Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"4259315236.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20181031"}]